Halozyme Therapeutics
HALO
HK$423.72
Share price
-1.03%
Change (1 day)
9.24%
Change (1 year)
Categories
Operating Margin for Halozyme Therapeutics (HALO)
Operating Margin as of June 2025 (TTM): 55.78%
According to Halozyme Therapeutics's latest financial reports and stock price the company's current Operating Margin is 55.78%. At the end of 2024 the company had an Operating Margin of 54.87%.
Operating Margin history for Halozyme Therapeutics from 2002 to 2025
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2024 | 54.87% | 30.63% |
| 2023 | 42.01% | 11.4% |
| 2022 | 37.71% | -32.74% |
| 2021 | 56.06% | 16.02% |
| 2020 | 48.32% | -231.08% |
| 2019 | -36.86% | -29.84% |
| 2018 | -52.54% | -370.02% |
| 2017 | 19.46% | -128.02% |
| 2016 | -69.44% | 190.97% |
| 2015 | -23.86% | -73.71% |
| 2014 | -90.76% | -40.42% |
| 2013 | -152.34% | 20.4% |
| 2012 | -126.53% | 258.95% |
| 2011 | -35.25% | -90.98% |
| 2010 | -390.79% | -8.46% |
| 2009 | -426.88% | -23.2% |
| 2008 | -555.87% | -24.97% |
| 2007 | -740.89% | -53.32% |
| 2006 | -1,587.26% | -84.79% |
| 2005 | -10,435.88% | |
| 2001 | -160.63% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 MannKind Corp MNKD | 11.16% | -79.99% | 🇺🇸 USA |
 Eli Lilly LLY | 27.75% | -50.25% | 🇺🇸 USA |
 Baxter BAX | -5.98% | -110.72% | 🇺🇸 USA |
 Pfizer PFE | 12.60% | -77.41% | 🇺🇸 USA |
 Sanofi SNY | 15.12% | -72.89% | 🇫🇷 France |
 Johnson & Johnson JNJ | 18.78% | -66.33% | 🇺🇸 USA |
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.